BST:RFL

Stock Analysis Report

Executive Summary

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.

Rewards

Trading at 96.4% below its fair value

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months

+ 1 more risk


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Tyme Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RFL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

15.4%

RFL

-2.0%

DE Biotechs

0.7%

DE Market


1 Year Return

-15.7%

RFL

5.6%

DE Biotechs

15.6%

DE Market

Return vs Industry: RFL underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: RFL underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

RFLIndustryMarket
7 Day15.4%-2.0%0.7%
30 Day96.6%-2.7%1.7%
90 Dayn/a9.4%6.3%
1 Year-15.7%-15.7%5.8%5.6%19.2%15.6%
3 Yearn/a59.0%57.2%18.3%7.9%
5 Yearn/a17.3%14.8%26.8%9.4%

Price Volatility Vs. Market

How volatile is Tyme Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Tyme Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RFL (€1.59) is trading below our estimate of fair value (€44.24)

Significantly Below Fair Value: RFL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RFL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RFL is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RFL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RFL is overvalued based on its PB Ratio (26.8x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Tyme Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

50.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RFL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RFL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RFL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if RFL's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if RFL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RFL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tyme Technologies performed over the past 5 years?

-32.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RFL is currently unprofitable.

Growing Profit Margin: RFL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RFL is unprofitable, and losses have increased over the past 5 years at a rate of -32.3% per year.

Accelerating Growth: Unable to compare RFL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RFL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: RFL has a negative Return on Equity (-390.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Tyme Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: RFL's short term assets ($16.0M) exceed its short term liabilities ($4.5M).

Long Term Liabilities: RFL's short term assets ($16.0M) exceed its long term liabilities ($5.7M).


Debt to Equity History and Analysis

Debt Level: RFL is debt free.

Reducing Debt: RFL currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: RFL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if RFL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RFL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RFL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -46.7% each year


Next Steps

Dividend

What is Tyme Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate RFL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RFL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RFL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RFL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RFL's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Tyme Technologies's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Steve Hoffman (56yo)

6.5yrs

Tenure

US$900,439

Compensation

Mr. Steven E. Hoffman, also known as Steve, has been the Chief Executive Officer of Tyme Technologies, Inc. since July 26, 2013. Mr. Hoffman co-founded Tyme Technologies, Inc. in 2011 and is its Chief Scie ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD900.44K) is above average for companies of similar size in the German market ($USD638.09K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.4yrs

Average Tenure

55yo

Average Age

Experienced Management: RFL's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Age and Tenure

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: RFL's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: RFL insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Sell€29,43514 Jan 20
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.47
Sell€26,21207 Jan 20
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.31
Sell€19,12131 Dec 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.96
Sell€17,54223 Dec 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.88
Sell€18,79518 Dec 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.94
Sell€19,51809 Dec 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.98
Sell€20,62503 Dec 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.03
Sell€20,49725 Nov 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.02
Sell€18,03819 Nov 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.90
Buy€9,32418 Nov 19
Steven Hoffman
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares10,000
Max Price€0.93
Buy€9,50518 Nov 19
James Biehl
EntityIndividual
Role
Chief Legal Officer
Chief Legal Officer & Secretary
Shares10,000
Max Price€0.95
Sell€21,08612 Nov 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.05
Sell€23,14104 Nov 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.16
Sell€25,18028 Oct 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.26
Sell€23,44521 Oct 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.17
Sell€25,79015 Oct 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.29
Sell€24,47208 Oct 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.22
Sell€25,54801 Oct 19
Michael Demurjian
EntityIndividual
Shares19,600
Max Price€1.30
Sell€52001 Oct 19
Michael Demurjian
EntityIndividual
Shares400
Max Price€1.30
Sell€30,40723 Sep 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.52
Sell€28,80517 Sep 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.44
Sell€22,31609 Sep 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.12
Sell€20,73003 Sep 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.04
Sell€19,79627 Aug 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.99
Sell€18,56920 Aug 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.93
Sell€17,81813 Aug 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€0.89
Sell€20,06606 Aug 19
Michael Demurjian
EntityIndividual
Shares20,000
Max Price€1.00
Sell€49,66530 Jul 19
Michael Demurjian
EntityIndividual
Shares50,000
Max Price€0.99
Sell€52,43523 Jul 19
Michael Demurjian
EntityIndividual
Shares50,000
Max Price€1.05
Buy€14,16818 Jun 19
James Biehl
EntityIndividual
Role
Chief Legal Officer
Chief Legal Officer & Secretary
Shares15,000
Max Price€0.94
Buy€28,60418 Jun 19
David Carberry
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares30,000
Max Price€0.95
Buy€14,43617 Jun 19
Steven Hoffman
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares15,000
Max Price€0.96
Buy€4,58917 Jun 19
Michele Korfin
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares5,000
Max Price€0.92
Buy€8,91117 Jun 19
Barbara Galaini
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer & Corporate Controller
Shares10,000
Max Price€0.89
Buy€9,00017 Jun 19
Ben Taylor
EntityIndividual
Role
President
President & CFO
Shares10,000
Max Price€0.90
Buy€57,82619 Feb 19
Douglas Michels
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares20,000
Max Price€2.89

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.


Management Team

  • Steve Hoffman (56yo)

    Co-Founder

    • Tenure: 6.5yrs
    • Compensation: US$900.44k
  • Jonathan Eckard (45yo)

    Chief Business Officer

    • Tenure: 0.8yrs
    • Compensation: US$2.29m
  • Jim Biehl (55yo)

    Chief Legal Officer & Secretary

    • Tenure: 1.3yrs
    • Compensation: US$1.70m
  • Giuseppe Del Priore (57yo)

    Chief Medical Officer

    • Tenure: 4.2yrs
    • Compensation: US$520.00k
  • Ben Taylor (42yo)

    President & CFO

    • Tenure: 2.8yrs
    • Compensation: US$1.41m
  • Barbara Galaini (61yo)

    Principal Accounting Officer & Corporate Controller

    • Tenure: 1.4yrs
  • Michele Korfin (47yo)

    Chief Operating Officer

    • Tenure: 0.8yrs
  • Brian Gill

    Head of Corporate Communications & IR

    • John Zucaro

      Senior Vice President of CMC


      Board Members

      • Tim Tyson (66yo)

        Independent Director

        • Tenure: 4.8yrs
        • Compensation: US$271.40k
      • Don DeGolyer (57yo)

        Independent Director

        • Tenure: 1.7yrs
        • Compensation: US$328.82k
      • Steve Hoffman (56yo)

        Co-Founder

        • Tenure: 6.5yrs
        • Compensation: US$900.44k
      • Tommy Thompson (77yo)

        Director

        • Tenure: 3.9yrs
        • Compensation: US$275.31k
      • Doug Michels (62yo)

        Independent Director

        • Tenure: 1.3yrs
        • Compensation: US$281.89k
      • Briggs Morrison (59yo)

        Member of Advisory Board

        • Tenure: 2.3yrs
      • David Carberry (67yo)

        Independent Director

        • Tenure: 2.8yrs
        • Compensation: US$288.80k
      • Paul Sturman (58yo)

        Independent Director

        • Tenure: 2.8yrs
        • Compensation: US$267.03k
      • Gerald Sokol (75yo)

        Independent Director

        • Tenure: 4.8yrs
        • Compensation: US$266.15k
      • Suresh Chari

        Member of Medical Advisory Board

        • Tenure: 4.3yrs

      Company Information

      Tyme Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: Tyme Technologies, Inc.
      • Ticker: RFL
      • Exchange: BST
      • Founded: 2011
      • Industry: Biotechnology
      • Sector: Pharmaceuticals & Biotech
      • Market Cap: US$217.190m
      • Listing Market Cap: US$195.971m
      • Shares outstanding: 112.53m
      • Website: https://www.tymeinc.com

      Number of Employees


      Location

      • Tyme Technologies, Inc.
      • 17 State Street
      • 7th Floor
      • New York
      • New York
      • 10004
      • United States

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      TYMENasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2015
      RFLBST (Boerse-Stuttgart)YesCommon StockDEEURMar 2015
      RFLDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2015

      Biography

      Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in Phase II clinical trials to treat cancer, including pancreatic, lung, breast, prostate, and sarcoma cancers. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2020/01/20 23:04
      End of Day Share Price2020/01/20 00:00
      Earnings2019/09/30
      Annual Earnings2019/03/31


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.